Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Scientists hunt for molecular proof that music helps Alzheimer's patients

NCT ID NCT07306065

Knowledge-focused Sponsor: University of Central Florida Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 31, 2026 · Updated 2 times

Summary

This study aims to scientifically prove that music therapy affects the brain in people with Alzheimer's disease. Researchers will measure brain-related molecules (like serotonin and dopamine) in saliva before and after music sessions. The study includes 60 adults: 20 with Alzheimer's or dementia, 20 with mild memory problems, and 20 healthy older adults. The goal is to link changes in these molecules to improvements in mood, thinking, and behavior.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

80 people

The number who actually took part.

Started

Aug 2025

Finished

May 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

50 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * 50 years old or older. * 20 adults with no mild-cognitive impairment * 20 adults with mild-cognitive impairment * 20 adults with Alzheimer's disease/ dementia. * participant or the participant's legally authorized representative must be able to read or speak English and agree to comply with study procedures. * pregnant women may chose to participate Exclusion Criteria: * 49 years and younger * prisoners * unable to understand English and provide consent

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Alzheimers disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Alzheimer disease dementia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Alzheimers disease Dementia Dementia Alzheimer type

Contacts and locations

Locations

  • University of Central Florida

    Orlando, Florida, 32827, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.